Literature DB >> 12921121

Immusorba TR and PH.

Noriko Hirata1, Toshiji Kuriyama, Naokuni Yamawaki.   

Abstract

Immusorba TR (IM-TR) and PH (IM-PH) were developed as adsorbents with non-biological materials as affinity ligands to remove pathogenic autoantibodies. The adsorbents of IM-TR and IM-PH are polyvinyl alcohol gel immobilized with tryptophan and phenylalanine as ligand, respectively. IM-TR is clinically applied for treatment of autoimmune neurological diseases such as myasthenia gravis and Guillain-Barre syndrome. IM-PH is used for not only neurological diseases such as GBS and multiple sclerosis but also collagen diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). As many autoantibodies with different specificities have been found to have similar affinities to the ligand of Immusorba, it is expected that Immusorba will be applied to more diseases and contribute to the clarification of the mechanisms of the development of diseases by the identification of adsorbed unknown pathogenic substances with Immusorba.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12921121     DOI: 10.1046/j.1526-0968.2003.00010.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  3 in total

Review 1.  Current topics in therapeutic plasmapheresis.

Authors:  Takeshi Nakanishi; Naoki Suzuki; Takahiro Kuragano; Yasuyuki Nagasawa; Yukiko Hasuike
Journal:  Clin Exp Nephrol       Date:  2013-07-26       Impact factor: 2.801

2.  Autoantibodies and Cardiomyopathy: Focus on Beta-1 Adrenergic Receptor Autoantibodies.

Authors:  Wai Hong Wilson Tang; Sathyamangla V Naga Prasad
Journal:  J Cardiovasc Pharmacol       Date:  2022-09-01       Impact factor: 3.271

Review 3.  Therapeutic Plasma Exchange: For Cancer Patients.

Authors:  Yuru Hu; Hanshan Yang; Shaozhi Fu; Jingbo Wu
Journal:  Cancer Manag Res       Date:  2022-02-02       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.